ArticleBMC pregnancy and childbirth2025
Total bile acid concentrations and adverse perinatal outcomes in chinese intrahepatic cholestasis of pregnancy including asymptomatic hypercholanemia of pregnancy: a retrospective cohort study.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development and application of a fluorescent immunochromatographic assay for metabolite G-DCA quantification in ICP.Journal of lipid research · 2026Article
- The Relationship Between Maternal Serum Afamin Levels and Intrahepatic Cholestasis of Pregnancy and Neonatal Outcomes.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEvidence concerning the association between excessive total bile acid (TBA) concentrations and adverse perinatal outcomes in the recent Chinese guidelines for intrahepatic cholestasis of pregnancy (C-ICP), which recommend including asymptomatic hypercholanemia of pregnancy (AHP) in ICP management, is insufficient. This study aims to investigate the association between adverse perinatal outcomes and maternal TBA concentrations in patients with C-ICP and compare differences in adverse perinatal outcomes between AHP and ICP subgroups in different TBA concentrations.
methodsThis retrospective cohort study included pregnant individuals with C-ICP (n = 957) who delivered and had regular antenatal examination records available at a hospital in Guangzhou, China, from January 2015 to December 2024. Participants were grouped according to TBA concentrations (low mild (LM), high mild (HM), severe (S), and extremely severe (ES)) and then sub-grouped into AHP and ICP subgroups within each TBA concentration group.
resultsMultivariate logistic regression models showed that the risk of adverse perinatal outcomes (including preterm birth, indicated preterm birth, meconium-stained amniotic fluid, and admission to the neonatology department) increased with TBA concentration. Compared to the LM group, the rate of adverse perinatal outcomes increased significantly from the S group onwards, reaching its highest rate in the ES group (preterm birth: P-trend < 0.001; indicated preterm birth: P-trend < 0.001; meconium-stained amniotic fluid: P-trend = 0.037; admission to the neonatology department: P-trend < 0.001; gestational age at delivery: P-trend < 0.001; birth weight of newborn: P-trend < 0.001). However, within the ES group, there was no significant difference in the risk of adverse perinatal outcomes between the AHP subgroup and the ICP subgroups. (preterm birth: odds ratio (OR) 0.41, 95% confidence interval (CI) 0.09-2.00; indicated preterm birth: OR 0.75, 95% CI 0.14-4.06; meconium-stained amniotic fluid: OR 0.56, 95% CI 0.14-2.19; admission to the neonatology department: OR 1.65, 95% CI 0.39-7.04; gestational age at delivery: β 0.65, 95% CI - 0.42-1.72; and birth weight of newborn: β 101.7, 95% CI - 129.05-332.45).
conclusionWe recommend TBA screening in prenatal care for all pregnant women, not just for those with pruritus. In addition, the AHP population can be followed with ICP-equivalent clinical management, which is indicated when TBA concentration is ≥ 100 μmol/L, as it increases the risk of adverse perinatal outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.